Nesina (alogliptin) is a diabetes drug that is linked to severe side effects like pancreatitis, pancreatic cancer, rhabdomyolysis, and more.
Do I Have a Texas Nesina Lawsuit? Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged. If you or a loved one was injured by Nesina, you should contact our lawyers immediately. You may be entitled to compensation by filing a Nesina lawsuit in Texas.
Nesina Side Effects
- Bile duct disease
- Bullous pemphigoid
- Gallbladder disease
- Heart failure
- Joint pain
- Pancreatic cancer and pancreatitis
FDA Evaluating Rhabdomyolysis Risk
The FDA is evaluating a potential signals of a serious risk and new safety information linking DPP4 diabetes drugs and rhabdomyolysis. This potentially life-threatening kidney side effect was identified by the FDA Adverse Event Reporting System (FAERS) between April and June 2017.
What is Nesina?
Nesina (alogliptin) is a diabetes drug that was developed by Takeda Pharmaceuticals and approved by the FDA in 2010. It belongs to a class of diabetes drugs called “incretin mimetics,” which work by mimicking metabolic hormones (incretins). Nesina inhibits the enzyme DPP-4, which extends the longevity of the hormone called GLP-1. This causes beta-cells in the pancreas to release more insulin into the bloodstream, which helps control blood-sugar levels.
Nesina and Heart Failure
A recent clinical trial found that 3.9% of patients on Nesina developed congestive heart failure, a serious condition in which the heart is unable to pump enough blood into the body.
In April 2016, the FDA issued a Safety Communication to warn that Nesina can increase the risk of heart failure. The risk is even higher for patients with pre-existing heart problems or kidney disease. The warnings came after the FDA reviewed two studies involving DPP-4 inhibitors:
- The EXAMINE clinical trial found that 109 patients on Nesina (3.9%) were hospitalized with heart failure vs. 3.3% (89 patients) on a placebo.
- The SAVOR clinical trial involving saxagliptin found a 27% increased rate of hospitalization for heart failure (3.5% vs. 2.8% on a placebo).
FDA Warning: Nesina and Severe Joint Pain
In August 2015, the FDA has issued a Safety Communication about the risk of severe, disabling joint pain from Nesina and other diabetes drugs in the DPP-4 inhibitor class. The warnings were issued after the agency identified 33 reports of severe, disabling joint pain in their database of adverse event reports since October 2006. Click here to read more.
Nesina and Pancreatic Cancer
Nesina’s effect on the pancreas is associated with pancreatitis (inflammation in the pancreas). Over time, chronic pancreatitis is a major risk-factor for pancreatic cancer. This is because inflammation increases the rate of cell death and growth, which in turn increases the risk of DNA mutations that cause cells to divide and grow out of control.
In March 2013, the FDA announced that they were investigating a potential risk of pancreatic cancer associated with Nesina. Researchers examined the pancreases of diabetic patients who died of unspecified causes while taking an “incretin mimetic” like Nesina. They found evidence of safety risks, including an “Increased risk of pancreatitis, or inflammation of the pancreas, and pre-cancerous cellular changes called pancreatic duct metaplasia.”
Incretin Mimetic Drugs and Cancer
Nesina treats type-2 diabetes by influencing DPP-4 and GLP-1 — similar to many other drugs in the “incretin mimetic” class. Several other drugs in this class have been linked to pancreatic cancer and thyroid cancer. These drugs include Januvia (sitagliptin), Byetta (exenatide), and Victoza (liraglutide).
- October 2009 — The FDA asked Amylin Pharmaceuticals, the manufacturer of Byetta, to “explore a potential signal of a serious risk of thyroid cancer and pancreatic cancer.”
- February 2011 — Gastroenterology investigates the FDA adverse event report database and publishes a study linking Januvia and Byetta to dozens of cases of pancreatic cancer and thyroid cancer.
- June 2011 — FDA publishes a Drug Safety Communication after a study of rodents given clinically-relevant doses of Victoza (liraglutide) developed malignant C-cell thyroid cancer.
- March 2013 — FDA publishes a Drug Safety Communication for Nesina and all incretin mimetic drugs after investigating evidence of pancreatitis and pancreatic cancer.
Nesina Class Action Lawyer
The Clark Firm, LLP is nationally recognized as a class action law firm in Texas. However, our trial attorneys are not filing a Nesina class action. Instead, we are filing individual lawsuits on behalf of people who were diagnosed with pancreatic cancer.
Do I have a Nesina Lawsuit in Texas?
Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged.
Collen’s amazing success in the courtroom and well known dedication to his clients has earned him the recognition of his peers as one of The Top Trial Lawyers in Texas.”
The Clark Firm has assembled a team of trial lawyers with more than 100 years experience, participation in over 600 jury trials and $260 million in verdicts and/or settlements. Please use the form below to contact us for a free Texas Nesina lawsuit review.